Conatus Pharmaceutic (CNAT) 2.29 $CNAT Conatus (CNAT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Conatus Pharmaceutic (CNAT) 2.29 $CNAT

Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.28 (+0.01)

BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.28 (+0.01)

Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:58AM CDT
Regeneron Pharmaceuticals (REGN), which is set to release second-quarter 2016 results on Aug 4, had recorded an average negative earnings surprise of 0.06% last quarter.
CNAT: 2.29 (+0.03), SNY: 41.92 (-0.57), REGN: 434.00 (+8.88)

Conatus Pharmaceuticals to Report Second Quarter 2016 Financial Results
GlobeNewswire - Wed Jul 27, 6:30AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the second quarter ended June 30, 2016, after the market close on Wednesday, August 3, 2016. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Wednesday, August 3, 2016, to discuss the financial results and provide a corporate update.
CNAT: 2.29 (+0.03)

Conatus to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York. The company is scheduled to engage in a "fireside chat" with a JMP Securities analyst and expects to host meetings with invited institutional investors. The company will post a current company overview presentation in the Investors section of its website at www.conatuspharma.com.
CNAT: 2.29 (+0.03)

Conatus (CNAT) Posts In Line Q1 Loss , Focus on Emricasan
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:32AM CDT
Conatus Pharmaceuticals (CNAT) reported first-quarter 2016 loss of 35 cents per share, in line with the Zacks Consensus Estimate.
VTL: 6.24 (+0.02), ANIP: 61.06 (+0.46), CNAT: 2.29 (+0.03), RTRX: 18.17 (+0.24)

Conatus' (CNAT) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:30AM CDT
Conatus' first-quarter 2016 loss of 35 cents per share came in line with consensus estimates.
CNAT: 2.29 (+0.03)

Conatus reports 1Q loss
Automated Insights - Thu May 05, 6:40AM CDT
SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Thursday reported a loss of $7.3 million in its first quarter.
CNAT: 2.29 (+0.03)

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates
GlobeNewswire - Thu May 05, 6:00AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2016, and provided updates on its development programs. After the market close yesterday, the company announced top-line results from the second stage of its Phase 2 Liver Cirrhosis trial. A conference call and webcast are scheduled for 8:00 a.m. ET today, as detailed below, to discuss both the trial results and financial results.
CNAT: 2.29 (+0.03)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 45.29 (unch), BIIB: 304.00 (+2.17), CNAT: 2.29 (+0.03), AMGN: 174.76 (+0.60), RPRX: 2.06 (-0.06), JNJ: 125.48 (+0.08), GILD: 80.60 (+0.14), GWPH: 96.11 (+1.79), GERN: 2.71 (+0.03), AVEO: 0.99 (-0.01), ICPT: 169.72 (-3.31), AGIO: 45.69 (+0.46), NVS: 83.27 (+0.20)

Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 50.40 (-0.07), IPXL: 31.15 (-0.27), CNAT: 2.29 (+0.03), JAZZ: 150.53 (-0.44)

Conatus Pharmaceuticals to Report First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Conatus will host a conference call and audio webcast at 8:00 a.m. Eastern Time on Thursday, May 5, 2016, to discuss the financial results and provide a corporate update.
CNAT: 2.29 (+0.03)

Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
GlobeNewswire - Mon Apr 18, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late breaker oral presentation at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016. The presentation (#LBO5) entitled, "Emricasan (IDN-6556) orally for three months in patients with cirrhosis and MELD scores 11-18 improves clinical parameters of cirrhosis in patients with baseline MELD score greater-than or equal to15," was delivered on Saturday, April 16, at 5:00 p.m. CET, by Catherine Frenette, M.D., Medical Director of Liver Transplantation at Scripps Clinic, La Jolla, CA, and a principal investigator in the company's multicenter Phase 2 Liver Cirrhosis clinical trial of emricasan. The presentation visuals are available in the Clinical Data section of the Conatus website at www.conatuspharma.com.
CNAT: 2.29 (+0.03)

Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment
GlobeNewswire - Fri Apr 15, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that a poster addressing results in both ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor, is being presented today at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016.
CNAT: 2.29 (+0.03)

Penny Stocks: Wednesday's List Of Trending Micro Cap And Small Cap Equities
ACCESSWIRE - Wed Apr 06, 11:25AM CDT
MIAMI, FL / ACCESSWIRE / April 6, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TRTC, NETE, SFOR, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
VCRA: 14.81 (+0.02), CNAT: 2.29 (+0.03)

Conatus to Present at Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016, at 9:20 a.m. ET, in New York. An audio webcast and copy of the presentation will be available in the Investors section of the company's website at www.conatuspharma.com.
CNAT: 2.29 (+0.03)

Penny Stocks To Buy: Traders Are Considering Stocks On This List, Monday 4/4/2016
ACCESSWIRE - Mon Apr 04, 10:43AM CDT
MIAMI, FL / ACCESSWIRE / April 4, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. ZFGN, CNAT, CRC, and TRTC have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
ZFGN: 3.17 (+0.13), CRC: 9.94 (-0.32), CNAT: 2.29 (+0.03)

Conatus Pharmaceuticals Appoints Edward F. Smith III as Senior Vice President, Regulatory Affairs and Quality Assurance
GlobeNewswire - Mon Apr 04, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of Edward F. Smith III, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance.
CNAT: 2.29 (+0.03)

Conatus Pharmaceuticals Announces Acceptance of Abstracts for EASL Meeting
GlobeNewswire - Wed Mar 30, 6:30AM CDT
- Late Breaker Oral Presentation of Phase 2 Liver Cirrhosis Trial Three-month Data -
CNAT: 2.29 (+0.03)

Conatus' Loss Narrower than Expected, Focus on Emricasan
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 8:00AM CST
Conatus Pharmaceuticals (CNAT) reported narrower-than-expected fourth-quarter 2015 loss of 30 cents per share.
CNAT: 2.29 (+0.03), BXLT: 46.02 (-0.18), ANIK: 50.64 (+0.72)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 68

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 126

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 204

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 94

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 60

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 94

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 79

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 146

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 95

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 50

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading

Top 5 Most Recently Viewed Articles

Forecasting a Surge: Aerial Work Platforms Market Insights

Updated Category News Views 111

Growth Forecast for Aerial Work Platforms Market The aerial work platforms (AWPs) market is projected to witness significant growth from 2025 to 2035. As safety regulations become more stringent and construction activities continue to rise, the demand for these platforms is expected to expand markedly. Currently valued at approximately USD 12.1 billion in 2025, industry...

Continue Reading
Three Defensive Stocks to Watch in the Consumer Staples Sector

Updated Category News Views 38

Three Defensive Stocks to Keep an Eye On This month, attention is drawn to three standout stocks in the consumer staples sector that have sparked interest among investors focused on stability and long-term growth. Understanding Momentum Indicators Momentum indicators, such as the Relative Strength Index (RSI), play a crucial role in trading decisions. The RSI measures how...

Continue Reading
Challenges Facing Homeownership in Canada: Key Insights Revealed

Updated Category News Views 196

Significant Barriers to Homeownership in Canada Recent findings highlight that 32% of Canadians are being blocked from purchasing their homes due to the challenge of saving for a down payment. This survey, conducted by CPA Canada and BDO Debt Solutions, reflects the increasing financial strain on potential homeowners amidst rising rent prices and stagnant wages....

Continue Reading
Walmex Antitrust Case Update: Insight from Company Executives

Updated Category News Views 115

Walmex Antitrust Case Update: Insight from Company Executives In the bustling retail landscape of Mexico, Walmex, the renowned local division of Walmart (NYSE: WMT), is under the discerning gaze of the antitrust authorities. The company is eagerly awaiting a crucial decision from the Federal Economic Competition Commission, commonly known as Cofece. This ruling is...

Continue Reading
Innovative EIF Catalyst Program Enhances EdTech Growth Opportunities

Updated Category News Views 267

EIF Catalyst, A Game-Changer for EdTech Entrepreneurs In a bold move to elevate the EdTech and workforce sectors, ECMC Group's Education Impact Fund has introduced the EIF Catalyst program. This initiative aims to support founders who are eager to scale their businesses but require guidance and investment. Transformative Educational Program The EIF Catalyst is a...

Continue Reading